Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
| ▸ | ACR | P10323 | 1/20 | 0.57 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.57 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196601 | 0.94 | PARP10 (0.54) | PARP10PRSS1ACRTMPRSS15NSD2 | |
| SCHEMBL6060174 | 0.92 | PARP10 (0.65) | PARP10NSD2NPC1RAB9AHPGD | |
| SCHEMBL70034 | 0.89 | PARP10 (0.70) | PARP10PRSS1ACRTMPRSS15NSD2 | |
| SCHEMBL28343302 | 0.89 | PARP10 (0.62) | PARP10PRSS1ACRTMPRSS15NPC1 | |
| SCHEMBL8205435 | 0.85 | PARP10 (0.78) | PARP10PRSS1ACRTMPRSS15NSD2 | |
| SCHEMBL31888 | 0.85 | PARP10 (0.70) | PARP10PRSS1ACRTMPRSS15NSD2 | |
| SCHEMBL1870544 | 0.85 | PARP10 (0.70) | PARP10PRSS1ACRTMPRSS15NSD2 | |
| Terephthalic Acid SCHEMBL28437942 | 0.83 | PARP10 (0.63) | PARP10PRSS1ACRTMPRSS15NSD2 | |
| SCHEMBL817796 | 0.83 | PARP10 (0.63) | PARP10PRSS1ACRTMPRSS15NSD2 | |
| SCHEMBL68278 | 0.83 | PARP10 (0.63) | PARP10PRSS1ACRTMPRSS15NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072151-A1 | SELECTIVE PARTIAL REDUCTION OF ESTERS USING GROUP IV TRANSITION METAL CATALYSTS AND USES THEREOF | BAYLOR UNIVERSITY (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250100984-A1 | SELECTIVE PARTIAL REDUCTION OF ESTERS USING GROUP IV TRANSITION METAL CATALYSTS AND USES THEREOF | BAYLOR UNIVERSITY (US) | 2025-03-27 | — | — | US | disclosed |
| CN-112110817-B | Method for preparing diaryl ester compound by high-efficiency catalysis of palladium pyridine | 陕西师范大学 | 2022-07-26 | — | — | CN | disclosed |
| CN-112110817-A | Method for preparing diaryl ester compound by high-efficiency catalysis of palladium pyridine | 陕西师范大学 | 2020-12-22 | — | — | CN | disclosed |
| US-8853207-B2 | Heterocyclic pyrazole compounds, method for preparing the same and use thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-10-07 | — | — | US | disclosed |
| US-20130274255-A1 | HETEROCYCLIC PYRAZOLE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-10-17 | — | — | US | disclosed |
| US-8410303-B2 | Direct conversion of phenols into amides and esters of benzoic acid | The Florida State University Research Foundation, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410303-B2 | Direct conversion of phenols into amides and esters of benzoic acid | The Florida State University Research Foundation, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| EP-1138712-A2 | Polyarylene copolymers and proton-conductive membrane | JSR Corporation (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-4411903-A | 4-[(Monosubstituted-alkyl)amino]benzoic acids and analogs as hypolipidemic and antiatherosclerotic agents | AMERICAN CYANAMID COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
| US-4311846-A | 4-[(Monosubstituted-alkyl) amino]benzoic acids and analogs as hypolipidemic and antiatherosclerotic agents | AMERICAN CYANAMID COMPANY (US) | 1982-01-19 | — | — | US | disclosed |
| US-4281018-A | HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4272546-A | ANTILIPEMIC, ANTIATHEROSCLEROTIC | AMERICAN CYANAMID COMPANY (US) | 1981-06-09 | — | — | US | disclosed |
| US-4254138-A | ANTILIPEMIC AGENTS AND ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1981-03-03 | — | — | US | disclosed |
| US-4245097-A | 4-[(Monosubstituted-alkyl) amino] benzoic acids and analogs as hypolipidemic and antiatherosclerotic agents | AMERICAN CYANAMID COMPANY (US) | 1981-01-13 | — | — | US | disclosed |
| US-4230628-A | HYPOLIPIDEMIC AGENTS, ANTIATHEROSCLEROSIS | AMERICAN CYANAMID COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4196208-A | ANTILIPEMIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | PARP10 2662/4885PRSS1 4598/4885ACR 4846/4885 |
| US-20250100984-A1 | SELECTIVE PARTIAL REDUCTION OF ESTERS USING GROUP IV TRANSITION METAL CATALYSTS AND USES THEREOF | ADH1A, ADH5, ADH1C | PARP10 332/4885PRSS1 1679/4885ACR 3073/4885 |
| US-20130274255-A1 | HETEROCYCLIC PYRAZOLE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF | RET, FLT3, FGFR1 | PARP10 3251/4885PRSS1 1067/4885ACR 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.